US bill aims to tackle rise in false patent marking suits
This article was originally published in Clinica
Executive Summary
A new bill introduced in the US House of Representatives aims to restrict the penalties that are being awarded to plaintiffs that have sued companies for alleged false patent markings. The Patent Lawsuit Reform Act of 2010, if signed into law, would bring relief to companies across all sectors – including pharmaceutical and medtech entities – that have been flooded with such lawsuits in the recent past.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
EMA To Get The Ball Rolling On Making CTIS Global
The European Medicines Agency wants to further improve the visibility of data in the Clinical Trials Information System by establishing it as a World Health Organization primary registry.